Figure 1. Recommended immunization schedule for persons aged 0 through 18 years –
United States, 2014.
(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).
These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1.
To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are in bold.
19–23
13–15
16–18
Vaccine
Birth
1 mo
2 mos
4 mos
6 mos
9 mos
12 mos
15 mos
18 mos
2-3 yrs
4-6 yrs
7-10 yrs
11-12 yrs
mos
yrs
yrs
Hepatitis B
(HepB)
1
dose
2
dose
3
dose
1
st
nd
rd
Rotavirus
(RV) RV1 (2-dose
2
See
1
dose
2
dose
st
nd
footnote 2
series); RV5 (3-dose series)
Diphtheria, tetanus, & acel-
1
st
dose
2
nd
dose
3
rd
dose
4
th
dose
5
th
dose
lular pertussis
(DTaP: <7 yrs)
3
Tetanus, diphtheria, & acel-
(Tdap)
lular pertussis
(Tdap: >7 yrs)
4
Haemophilus influenzae type
See
3
rd
or 4
th
dose,
1
dose
2
dose
st
nd
footnote 5
See footnote 5
b
(Hib)
5
Pneumococcal conjugate
6
1
st
dose
2
nd
dose
3
rd
dose
4
th
dose
(PCV13)
Pneumococcal polysaccha-
ride
(PPSV23)
6
Inactivated poliovirus
(IPV)
7
1
dose
2
dose
3
dose
4
dose
st
nd
rd
th
(<18 yrs)
Influenza
(IIV; LAIV) 2 doses
8
Annual vaccination (IIV only)
Annual vaccination (IIV or LAIV)
for some: See footnote 8
Measles, mumps, rubella
9
2
dose
1
dose
nd
st
(MMR)
Varicella
(VAR)
1
dose
2
nd
dose
1 0
st
Hepatitis A
(HepA)
2-dose series, See footnote 11
11
Human papillomavirus
1 2
(3-dose
(HPV2: females only; HPV4:
series)
males and females)
Meningococcal
(Hib-Men-
1 3
CY > 6 weeks; MenACWY-D
See footnote 13
1
dose
st
Booster
>9 mos; MenACWY-CRM
≥ 2 mos)
Range of
Range of recommended
Range of recommended
Range of recommended ages
Not routinely
recommended ages for
ages for catch-up
ages for certain high-risk
during which catch-up is
recommended
all children
immunization
groups
encouraged and for certain
high-risk groups
This schedule includes recommendations in effect as of January 1, 2014. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination
vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed
recommendations, available online at Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System
(VAERS) online ( ) or by telephone (800-822-7967).Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including
precautions and contraindications for vaccination, is available from CDC online
( )
or by telephone (800-CDC-INFO [800-232-4636]).
This schedule is approved by the Advisory Committee on Immunization Practices (http// ), the American Academy of Pediatrics ( ), the American Academy of Family Physicians
( ), and the American College of Obstetricians and Gynecologists ( ).
NOTE: The above recommendations must be read along with the footnotes of this schedule.